Jagota Pharma & Sons Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
- Paid Up Capital ₹ 4.00 M
- Company Age 10 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 Cr
- Satisfied Charges ₹ 1.25 Cr
- Revenue Growth -0.43%
- Profit Growth 2.39%
- Ebitda 4.38%
- Net Worth 5.24%
- Total Assets 0.31%
About Jagota Pharma & Sons
Jagota Pharma & Sons Private Limited (JPSPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 12 June 2014 and has a history of Ten years and eight months. Its registered office is in Bareilly, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹2.00 Cr. The company has closed loans amounting to ₹1.25 Cr, as per Ministry of Corporate Affairs (MCA) records.
Minisha Bass and Rakesh Bhandari serve as directors at the Company.
Company Details
- Location
Bareilly, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74900UP2014PTC064316
- Company No.
064316
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jun 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Jagota Pharma & Sons?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Minisha Bass  | Director | 12-Jun-2014 | Current |
| Rakesh Bhandari | Director | 12-Jun-2014 | Current |
Financial Performance of Jagota Pharma & Sons.
Jagota Pharma & Sons Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.43% decrease. The company also saw a slight improvement in profitability, with a 2.39% increase in profit. The company's net worth moved up by a moderate rise of 5.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jagota Pharma & Sons?
In 2023, Jagota Pharma & Sons had a promoter holding of 69.50% and a public holding of 30.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹20.00 M
₹12.50 M
Charges Breakdown by Lending Institutions
- Others : 2.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Aug 2017 | Others | ₹2.00 Cr | Open |
| 07 May 2015 | Punjab And Sind Bank | ₹1.25 Cr | Satisfied |
How Many Employees Work at Jagota Pharma & Sons?
Unlock and access historical data on people associated with Jagota Pharma & Sons, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jagota Pharma & Sons, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jagota Pharma & Sons's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
